Related Experiment Video
Updated: Jun 23, 2025

12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.7K
A Hybrid Approach to Hood-Sparing Robotic Prostatectomy to Maximize Functional Outcomes and Maintain Early Oncologic
Ethan H Vargo1, Joel M Vetter1, R Sherburne Figenshau1
1Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Journal of Endourology
|June 15, 2024
Summary
The hybrid hood-sparing (HS) robot-assisted radical prostatectomy (RARP) offers faster recovery of continence and sexual function, comparable to retzius-sparing (RS) RARP. This approach achieves early oncologic control similar to traditional retropubic (RP) RARP.
Area of Science:
- Urology
- Surgical Oncology
- Robotic Surgery
Background:
- Robot-assisted radical prostatectomy (RARP) is a standard treatment for prostate cancer.
- Different surgical approaches, including retropubic (RP), retzius-sparing (RS), and hood-sparing (HS), aim to optimize oncologic and functional outcomes.
- The hybrid HS-RARP technique combines aspects of existing methods to potentially improve patient recovery.
Purpose of the Study:
- To evaluate the oncologic and functional outcomes of a hybrid hood-sparing (HS) robot-assisted radical prostatectomy (RARP).
- To compare the HS-RARP approach with traditional retropubic (RP) and retzius-sparing (RS) RARP.
- To assess the efficacy and safety of the novel hybrid HS-RARP technique.
Main Methods:
- Retrospective review of 200 patients undergoing RARP by a single surgeon.
- Propensity-matched comparison of three cohorts: traditional RP (n=80), RS (n=40), and HS (n=80).
- Analysis of patient characteristics, oncologic outcomes (positive margin rates, recurrence, metastasis), and functional outcomes (continence, sexual function).
Main Results:
- Patient characteristics were similar across cohorts, with lower PSA in the RS group.
- Clinically significant positive margin rates were higher in the RS cohort (32.5%) compared to RP (17.5%) and HS (13.9%).
- Median time to continence was significantly shorter for RS (1.3 months) and HS (1.6 months) compared to RP (5.4 months).
- Median time to return of sexual function was significantly shorter for RS (4.0 months) and HS (7.7 months) compared to RP (15.1 months).
Conclusions:
- The hybrid HS-RARP approach demonstrates functional outcomes comparable to RS-RARP.
- This technique achieves early oncologic control similar to traditional RP-RARP.
- Hybrid HS-RARP offers a promising alternative for patients seeking improved functional recovery with effective cancer control.

